Gut dysbiosis and multiple sclerosis
DOI:
https://doi.org/10.18203/2349-3933.ijam20253869Keywords:
Multiple sclerosis, Gut dysbiosis, Gut–brain axis, NeuroinflammationAbstract
Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system marked by multifocal demyelination, neuroinflammation, and progressive neurodegeneration. Globally, it affects about 2.9 million people, creating significant personal, social, and economic burdens. In India, approximately 100,000 to 150,000 individuals live with MS, with prevalence estimates ranging from 8-11 per 100,000 population, and an estimated 6,500 new diagnoses annually. MS imposes a heavy healthcare burden: early diagnosis is often delayed due to low awareness, limited access to neurologists, and inconsistent diagnostic protocols leading to prolonged hospital stay, longer duration of clinically undiagnosed disease and worse overall outcomes. In India, clinical management of MS faces a multitude of challenges in the form of inadequacies in diagnostic ability arising due to lack of advanced training, medical supplies, diagnostic tools and lack of trained neurologists per capita. Additionally, drugs used to manage MS are often expensive and require longer durations of therapy and frequent adjustments on follow up, leading to financial exhaustion for the patient, and subsequently adding to their inaccessibility. In recent years, there has been evidence suggesting a correlation of altered composition of gut commensals with CNS autoimmune diseases like MS. This association opens new avenues for understanding, diagnosing and managing such diseases beyond conventional neurotropic therapy. Any deviation from normal in the gut flora can trigger oxidative damage, that promotes mitochondrial dysfunction, and sets in motion cascades of inflammation via the gut brain axis that eventually led to demyelination and degeneration. Also, various humoral, endocrine and immune connections exist between the gut and brain, that influence release of neurotransmitters, peptides and cytokines that further serve to modify CNS function. This review aims to consolidate evidence that corroborates the link between gut dysbiosis and MS.
Metrics
References
Zhang W, Wang Y, Zhu M, Liu K, Zhang HL. Gut flora in multiple sclerosis: implications for pathogenesis and treatment. Neural Regeneration Res. 2024;19(7):1480-18. DOI: https://doi.org/10.4103/1673-5374.387974
Falabella M, Vernon HJ, Hanna MG, Claypool SM, Pitceathly RDS. Cardiolipin, Mitochondria, and Neurological Disease. Trends Endocrinol Metabol. 2021;32(4):224-37. DOI: https://doi.org/10.1016/j.tem.2021.01.006
Alves LB, Giuliatti S. Multivariate conformational patterns may distinguish HLA-DRB1 alleles associated with Multiple Sclerosis susceptibility. Brazilian Symposium on Bioinformatics. 2025;1-2.
Zhou J, Zhang Z, Zhou K, Zhou L, Xue J, Liu B, et al. PLA2R1 and HLA-DQA1 SNP in patients with primary membranous nephropathy. PLoS One. 2025;20(8):e0328234. DOI: https://doi.org/10.1371/journal.pone.0328234
Hall JE. Guyton and Hall Textbook of Medical Physiology. 14th ed. Philadelphia, PA: Elsevier. 2021;799-803.
Hauser SL, Cree BAC. Multiple sclerosis and other demyelinating diseases. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 21st ed. New York, NY: McGraw Hill. 2022:3395-414.
Sahani KK, Gupta H. Association between vitamin D deficiency and angiographic severity in patients with coronary artery disease. Int J Cardiovascular Acad. 2024;10(4):132-8. DOI: https://doi.org/10.4274/ijca.2024.51523
Pandit L, Ramagopalan SV, Malli C, D’Cunha A, Kunder R, Shetty R. Association of vitamin D and multiple sclerosis in India. Mult Scler J. 2013;19(12):1592-6. DOI: https://doi.org/10.1177/1352458513482375
Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):28328. DOI: https://doi.org/10.1001/jama.296.23.2832
Morali K, Giacomello G, Vuono M, Gregori S. Leveraging current insights on IL‐10‐producing dendritic cells for developing effective immunotherapeutic approaches. Febs Letters. 2025;599(14):2025-47. DOI: https://doi.org/10.1002/1873-3468.15017
Singhal BS, Advani H. Multiple sclerosis in India: An overview. Ann Indian Acad Neurol. 2015;18(1):S2-5. DOI: https://doi.org/10.4103/0972-2327.164812
Paul O'Connor, James Marriott, Multiple Sclerosis, Chapter 2, Differential Diagnosis and Diagnostic Criteria for Multiple Sclerosis: Application and Pitfalls. 2010.
Smolders J, Torkildsen Ø, Camu W, Holmøy T. An update on vitamin D and disease activity in multiple sclerosis. CNS Drugs. 2019;33(12):1187-99. DOI: https://doi.org/10.1007/s40263-019-00674-8
Lanz TV, Brewer RC, Ho PP, Jae-Seung M, Kevin MJ, Daniel F, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321-7. DOI: https://doi.org/10.1038/s41586-022-04432-7
Bjornevik K, Cortese M, Healy BC, Jens K, Michael JM, Yumei L, et al. Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301 DOI: https://doi.org/10.1126/science.abj8222
Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21(1):5164. DOI: https://doi.org/10.1038/s41579-022-00770-5
Briggs FB, Gunzler DD, Ontaneda D, Marrie RA. Smokers with MS have greater decrements in quality of life and disability than non-smokers. Mult Scler J. 2017;23(13):1772-81. DOI: https://doi.org/10.1177/1352458516685169
O'Gorman C, Lucas R, Taylor B. Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci. 2012;13(9):11718-52. DOI: https://doi.org/10.3390/ijms130911718
Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-9.
Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024;9(1):37.
Liu L, Huh JR, Shah K. Microbiota and the gut-brainaxis: Implications for new therapeutic design in the CNS. eBioMedicine 2022;77:103908. DOI: https://doi.org/10.1016/j.ebiom.2022.103908
Zhao M, Chu J, Feng S, Guo C, Xue B, He K, et al. Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review. Biomed Pharmacother. 2023;164:114985. DOI: https://doi.org/10.1016/j.biopha.2023.114985
Shim JA, Ryu JH, Jo Y, Hong C. The role of gut microbiota in T cell immunity and immune mediated disorders. Int J Biol Sci. 2023;19(4):1178-91. DOI: https://doi.org/10.7150/ijbs.79430
Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492-506. DOI: https://doi.org/10.1038/s41422-020-0332-7
Choden T, Cohen NA. The gut microbiome and the immune system. Explor Med. 2022;3:219-33. DOI: https://doi.org/10.37349/emed.2022.00087
Lee N, Kim WU. Microbiota in T-cell homeostasis and inflammatory diseases. Exp Mol Med. 2017;49(5):e340. DOI: https://doi.org/10.1038/emm.2017.36
Lambring CB, Siraj S, Patel K, Sankpal UT, Mathew S, Basha R. Impact of the Microbiome on the Immune System. Crit Rev Immunol. 2019;39(5):313-28. DOI: https://doi.org/10.1615/CritRevImmunol.2019033233
Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria. Cell. 2009;139(3):485-98. DOI: https://doi.org/10.1016/j.cell.2009.09.033
Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2021;3(1):4-14. DOI: https://doi.org/10.4161/gmic.19320
Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024;9(1):37. DOI: https://doi.org/10.1038/s41392-024-01743-1
Ding YH, Qian LY, Pang J, Lin JY, Xu Q, Wang LH, et al. The regulation of immune cells by Lactobacilli: A potential therapeutic target for anti-atherosclerosis therapy. Oncotarget. 2017;8(35):59915-28. DOI: https://doi.org/10.18632/oncotarget.18346
Montgomery TL, Peipert D, Krementsov DN. Modulation of multiple sclerosis risk and pathogenesis by the gut microbiota: Complex interactions between host genetics, bacterial metabolism, and diet. Immunological rev. 2024;325(1):131-51. DOI: https://doi.org/10.1111/imr.13343
Lan M, Tang X, Zhang J, Yao Z. Insights in pathogenesis of multiple sclerosis: Nitric oxide may induce mitochondrial dysfunction of oligodendrocytes. Rev Neurosci. 2018;29(1):39-53.
Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15(3):292-303. DOI: https://doi.org/10.1016/S1474-4422(15)00393-2
Ferraro D, Veronica G, Francesca V, Anna MS, Roberta B, Cinzia DG, et al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis. J Neuroimmunol. 2015;283:64-9. DOI: https://doi.org/10.1016/j.jneuroim.2015.04.011
Abdel Naseer M, Rabah AM, Rashed LA, Hassan A, Fouad AM. Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis. Mult Scler Relat Disord. 2020;38:101873. DOI: https://doi.org/10.1016/j.msard.2019.101873
Lan M, Tang X, Zhang J, Yao Z. Insights in pathogenesis of multiple sclerosis: Nitric oxide may induce mitochondrial dysfunction of oligodendrocytes. Rev Neurosci. 2018;29(1):39-53. DOI: https://doi.org/10.1515/revneuro-2017-0033
Mathur D, Mishra BK, Rout S, Lopez-Iranzo FJ, Lopez-Rodas G, Vallamkondu J, et al. Potential biomarkers associated with multiple sclerosis pathology. Int J Mol Sci. 2021;22(19):10323. DOI: https://doi.org/10.3390/ijms221910323
Farina G, Magliozzi R, Pitteri M, Reynolds R, Rossi S, Gajofatto A, et al. Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: A combined CSF and MRI study. J Neuroinflamm. 2017;14(1):40. DOI: https://doi.org/10.1186/s12974-017-0812-y
Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775-83. DOI: https://doi.org/10.1002/ana.24617
Ayrignac X, Le Bars E, Duflos C, Hirtz C, MaleskaMaceski A, Carra-Dallière C, et al. Serum GFAP in multiple sclerosis: Correlation with disease type and MRI markers of disease severity. Sci Rep. 2020;10(1):10923. DOI: https://doi.org/10.1038/s41598-020-67934-2
Mirzaii-Dizgah MH, Mirzaii-Dizgah MR, MirzaiiDizgah I. Serum and saliva Myelin basic protein as Multiple sclerosis biomarker. Basic Clin Neurosci. 2021;12(3):309-14. DOI: https://doi.org/10.32598/bcn.2021.950.2
Sharma N, Shandilya A, Kumar N, Mehan S. Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions. Endocr Metab Immune Disord Drug Targets. 2021;21(10):1845-68. DOI: https://doi.org/10.2174/1871530321666210309112234
Karimi M, Shirsalimi N, Hashempour Z, Omran HS, Sedighi E, Beigi F, et al. Safety and efficacy of fecal microbiota transplantation (FMT) as a modern adjuvant therapy in various diseases and disorders: A comprehensive literature review. Front Immunol. 2024;15:1439176. DOI: https://doi.org/10.3389/fimmu.2024.1439176
Downloads
Published
How to Cite
Issue
Section
